Solid tumour indications will be much easier to recruit patients for than a subset of a rare cancer indication in EMD AML. Furthermore, with the right quantum of investment by Otsuka, the appropriate experts can be brought in to facilitate/oversee the trial/s.
Perhaps Otsuka would like to see the remaining boxed ticked with GMP and final tox studies for bisantrene given their natural disposition to risk aversion, so maybe we will hear more from July onwards.
Nothing preventing Pete getting on a plane to Japan in the meantime to progress/expand the current commercial relationship well beyond the investigator led AML trial.
Solid tumour indications will be much easier to recruit patients...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.035(2.18%) |
Mkt cap ! $266.3M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.56 | $101.6K | 64.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7451 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 408 | 1 |
View Market Depth
| Last trade - 15.53pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.58 |
Change
-0.035 ( 1.25 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.62 | $1.56 | 7255 | ||
| Last updated 15.57pm 05/06/2024 ? | |||||
| RAC (ASX) Chart |